Li F, Liu M, Guo C, Xu R, Li F, Liu Z, Pan Y, Liu F, Liu Y, Cai H, He Z, Ke Y. Cost-effectiveness of precision screening for esophageal cancer based on individualized risk stratification in China: Real-world evidence from the ESECC trial,Front Oncol,Front Oncol. 2022 Nov 30;12:1002693. doi: 10.3389/fonc.2022.1002693. eCollection 2022.

Liu Z, Zheng H, Liu M, He Y, Chen Y, Ji P, Fang Z, Xiao P, Li F, Guo C, Yin W, Pan Y, He Z, Ke Y. Development and External Validation of an Improved Version of the Diagnostic Model for Opportunistic Screening of Malignant Esophageal Lesions,Cancers (Basel),Cancers (Basel). 2022 Nov 30;14(23):5945. doi: 10.3390/cancers14235945.

Qi Z, Liu M, Zhou R, Guo C, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Wu N, Liu Z, Pan Y, Liu F, Liu Y, Cai H, He Z, Ke Y. Multiple Lugol-unstained lesions predict higher cumulative risk of malignance in the esophagus,J Gastroenterol Hepatol,J Gastroenterol Hepatol. 2023 Mar;38(3):416-423. doi: 10.1111/jgh.16075. Epub 2022 Dec 7.

Liang L, Liu F, He Z, Ke Y. ASO Author Reflections: A Novel Blood-Based Predictor (MF-A) That Independently Influences the Prognosis of ESCC Patients Receiving Esophagectomy,Ann Surg Oncol,Ann Surg Oncol. 2022 Sep;29(9):5634-5635. doi: 10.1245/s10434-022-11428-0. Epub 2022 Jul 11.

Liu M, Liu Y, Zhou R, Liu Z, Guo C, Xu R, Li F, Liu A, Yang H, Zhang S, Shen L, Duan L, Wu Q, Zhao M, Su H, Liu F, Pan Y, Cai H, He Z, Ke Y. Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions,J Pathol,J Pathol. 2022 Sep;258(1):38-48. doi: 10.1002/path.5970. Epub 2022 Jun 30.

Liu M, Zhou R, Liu Z, Guo C, Xu R, Zhou F, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Zheng H, Tian H, Liu F, Liu Y, Pan Y, Chen H, Hu Z, Cai H, He Z, Ke Y. Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general population,EClinicalMedicine,EClinicalMedicine. 2022 Apr 16;47:101394. doi: 10.1016/j.eclinm.2022.101394. eCollection 2022 May.

Li F, Hu Y, Guo C, Lei L, Li F, Liu M, Liu Z, Pan Y, Liu F, Liu Y, Hu Z, Chen H, He Z, Ke Y. Economic Burden Conferred by Population-Level Cancer Screening on Resource-Limited Communities: Lessons From the ESECC Trial,Front Oncol,Front Oncol. 2022 Mar 21;12:849368. doi: 10.3389/fonc.2022.849368. eCollection 2022.

M. Liu#, Z. Liu#, F. Liu#, C. Guo, R. Xu, F. Li, A. Liu, H. Yang, S. Zhang, L. Shen, L. Duan, Q. Wu, C. Cao, Y. Pan, Y. Liu, J. Li, H. Cai, Z. He* and Y. Ke*. Absence of Iodine Staining Associates With Progression of Esophageal Lesions in a Prospective Endoscopic Surveillance Study in China.,Clin Gastroenterol Hepatol,18(7): 1626-1635.

Liu F#, Liu M#, Liu Y#, Guo C, Zhou Y, Li F, Xu R, Liu Z, Deng Q, Li X, Zhang C, Pan Y, Ning T, Dong X, Hu Z, Bao H, Cai H, Silva IDS*, He Z*, and Ke Y*,Chin J Cancer Res,32(6): 742-754

Z. He and Y. Ke, Precision screening for esophageal squamous cell carcinoma in China.,Chin J Cancer Res,32(6):673-682

Z. Liu#, C. Guo#, Y. He#, Y. Chen#, P. Ji#, Z. Fang#, F. Li, Y. Tang, X. Chen, P. Xiao, C. Wang, W. Yin, H. Guo, M. Liu, Y. Pan, F. Liu, Y. Liu, Z. He*, and Y. Ke*, A clinical model predicting the risk of esophageal high-grade lesions in opportunistic screening: a multicenter real-world study in China.,Gastrointest Endosc,91(6):1253-1260.

M. Wang#, M. Liu#, F. Li, C. Guo, Z. Liu, Y. Pan, Y. Liu, F. Liu, H. Cai, Y. Wu, Z. He*, and Y. Ke*, Gender heterogeneity in dyslipidemia prevalence, trends with age and associated factors in middle age rural Chinese.,Lipids Health Dis,19(1): 135.

H. Tian#, W. Yang#, Y. Hu#, Z. Liu#, L. Chen, L. Lei, F. Zhang, F. Cai, H. Xu, M. Liu, C. Guo, Y. Chen, P. Xiao, J. Chen, P. Ji, Z. Fang, F. Liu, Y. Liu, Y. Pan, I. Dos-Santos-Silva, Z. He*, and Y. Ke*, Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China.,EClinicalMedicine,20: 100312.

H. Tian, R. Xu, F. Li, C. Guo, L. Zhang, Z. Liu, M. Liu, Y. Pan, Z. He*, Y. Ke.Identification of cancer patients using claims data from health insurance systems: A real-world comparative study.,Chin J Cancer Res,31(4): 699-706.

C. Shi#, M. Liu#, Z. Liu, C. Guo, F. Li, R. Xu, F. Liu, Y. Liu, J. Li, H. Cai, Z. He* and Y. Ke* . Using Health Insurance Reimbursement Data to Identify Incident Cancer Cases.,J Clin Epidemiol,114:141-149.

Liu M#, Zhou R#, Liu Z#, Guo C, Xu R, Zhou F, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Zheng H, Tian H, Liu F, Liu Y, Pan Y, Chen H, Hu Z, Cai H, He Z*, and Ke Y*. Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general population.,EClinicalMedicine,47:101394.

Li F, Hu Y, Guo C, Lei L, Li F, Liu M, Liu Z, Pan Y, Liu F, Liu Y, Hu Z, Chen H, He Z*, and Ke Y*. Economic Burden Conferred by Population-Level Cancer Screening on Resource-Limited Communities: Lessons from the ESECC Trial.,Front Oncol,12:849368

Zhou R#, Zheng H#, Liu M#, Liu Z#, Guo C, Tian H, Liu F, Liu Y, Pan Y, Chen H, Hu Z, Cai H, He Z*, and Ke Y*. Development and validation of a questionnaire-based risk scoring system to identify individuals at high risk for gastric cancer in Chinese populations.,Chin J Cancer Res,33(6):649-658.

Wang M#, Liu M#, Guo C, Li F, Liu Z, Pan Y, Liu F, Liu Y, Bao H, Hu Z, Cai H, He Z*, and Ke Y*. Association of early-life undernutrition and risk of dyslipidemia in adulthood: a population-based cohort study.,BMC Public Health,21(1): 2129.

Wang M#, Liu F#, Pan Y#, Xu R, Li F, Liu A, Yang H, Duan L, Shen L, Wu Q, Liu Y, Liu M, Liu Z, Hu Z, Chen H, Cai H, He Z*, and Ke Y*. Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?,EBioMedicine,73: 103674.

Liu M#, Zhou R#, Guo C, Xu R, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Liu Z, Liu F, Liu Y, Pan Y, Cai H, Weiss NS*, He Z* and Ke Y*. Size of Lugol-unstained lesions as a predictor for risk of progression in premalignant lesions of the esophagus.,Gastrointest Endosc,93(5):1065-1073.

Precision screening for esophageal squamous cell carcinoma in China,Chinese Journal of Cancer Research,32(6):673-682

精准健康管理, 参编, 北京大学医学出版社, 2020.10

恶性肿瘤精准防治技术与策略

人群与临床大数据的挖掘与转化应用

恶性肿瘤多组学与分子流行病学

胃癌高低发区影响因素的综合调查, 子课题负责人, 2020.1.1～2022.12.31, 国家科技部

基于前瞻性队列的食管癌早期预警生物标志物筛选及风险预测研究, 2020.11.1～2023.10.31, 北京市自然科学基金京津冀基础研究合作专项

食管癌专病队列研究—高发现场食管癌及其癌前病变人群前瞻性队列研究, 子课题负责人, 2016.7.1～2020.12.31, 国家重点研发计划“精准医学研究 (2016YFC0901404)

基于前瞻性队列的食管癌早期预警生物标志物筛选及风险预测研究, 课题负责人, 2021.1.1～2022.12.31, 北京市百千万人才工程

基于前瞻性人群队列的食管癌早期预警生物标志物筛选及风险预测研究, 课题负责人, 2021.1.1～2024.12.31, 国家自然科学基金面上项目

基于前瞻性人群队列的食管癌早期预警生物标志物筛选及风险预测研究, 课题负责人, 2021.1.1～2024.12.31, 国家自然基金面上项目

常见恶性肿瘤联合早筛模式的建立及卫生经济学评价, 子课题负责人, 2021.12.1～2024.11.30, 国家重点研发计划

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2024	流行病与卫生统计学	博士	科学学位	上消化道恶性肿瘤精准防治的人群现场与分子流行病学；临床大数据分析与挖掘	申请考核制